Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Individuals

被引:46
|
作者
Lazzaretti, Rosmeri K. [1 ]
Kuhmmer, Regina [1 ]
Sprinz, Eduardo [2 ,3 ]
Polanczyk, Carisi A. [1 ,3 ]
Ribeiro, Jorge P. [1 ,3 ]
机构
[1] Hosp Clinicas Porto Alegre, Div Cardiol, BR-90035007 Porto Alegre, RS, Brazil
[2] Hosp Clinicas Porto Alegre, Div Internal Med, Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Fac Med, Dept Med, Porto Alegre, RS, Brazil
关键词
AIDS; cholesterol; nutrition; HIV-INFECTED PATIENTS; PROTEASE INHIBITOR; CHOLESTEROL; AIDS; MANAGEMENT; TRIALS; ADULTS; LIPIDS; RECOMMENDATIONS; LIPODYSTROPHY;
D O I
10.1016/j.jacc.2011.11.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to evaluate the efficacy of dietary intervention on blood lipids of human immunodeficiency virus (HIV)-1-infected patients who are started on highly active antiretroviral therapy (HAART). Background Current guidelines recommend diet as first-step intervention for HIV-1-infected individuals with HAART-related dyslipidemia, but there is no evidence from randomized trials to support this recommendation. Methods Eighty-three HIV-1-infected patients, naive from HAART, were randomly assigned to HAART with dietary intervention (diet group, n = 43) or HAART without dietary intervention (control group, n = 40) for 12 months. Diet, according to the National Cholesterol Education Program, was given every 3 months. Before and after intervention, 24-h food records and lipid profile were obtained. Data were analyzed by intention to treat, using mixed-effects models. Results Diet resulted in reduction of percentage of fat intake (from 31 +/- 7% to 21 +/- 3% of calories), while controls presented no change in percentage of fat intake. Plasma cholesterol (from 151 +/- 29 mg/dl to 190 +/- 33 mg/dl) and low-density lipoprotein cholesterol (from 85 +/- 24 mg/dl to 106 +/- 31 mg/dl) increased in the control group and were unchanged in the diet group. Plasma triglycerides were reduced by diet (from 135 +/- 67 mg/dl to 101 +/- 42 mg/dl) and increased in the control group (from 134 +/- 70 mg/dl to 160 +/- 76 mg/dl). After 1-year follow-up, 21% of patients who received diet had lipid profile compatible with dyslipidemia compared with 68% (p < 0.001) of controls. Conclusions Among HIV-1-positive individuals naive of previous treatment, diet prevents dyslipidemia associated with HAART. (Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial; NCT00429845) (J Am Coll Cardiol 2012;59:979-88) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:979 / 988
页数:10
相关论文
共 50 条
  • [1] Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in HIV-1-infected individuals: a randomized trial
    Ribeiro, J. P.
    Lazzaretti, R. K.
    Kuhmmer, R.
    Polanczyk, C. A.
    Sprinz, E.
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 : 213 - 213
  • [2] Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth
    Verweel, G
    van Rossum, AMC
    Hartwig, NG
    Wolfs, TFW
    Scherpbier, HJ
    de Groot, R
    [J]. PEDIATRICS, 2002, 109 (02) : E25
  • [3] Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: Analysis of cellular immune responses
    Blazevic, V
    Jankelevich, S
    Steinberg, SM
    Jacobsen, F
    Yarchoan, R
    Shearer, GM
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (05) : 943 - 948
  • [4] The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients
    Jensen-Fangel, S
    Pedersen, L
    Pedersen, C
    Larsen, CS
    Tauris, P
    Moller, A
    Sorensen, HT
    Obel, N
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (12) : 1541 - 1548
  • [5] Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years
    Zhou, Hua-Ying
    Zheng, Yu-Huang
    Zhang, Chun-Ying
    Chen, Jun
    He, Yan
    Ding, Pei-Pei
    Li, Hui
    [J]. VIRAL IMMUNOLOGY, 2007, 20 (01) : 180 - 187
  • [6] Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency
    Resino, S
    Alvaro-Meca, A
    de José, MI
    Martin-Fontelos, P
    Gutiérrez, MDG
    Léon, JA
    Ramos, JT
    Ciria, L
    Muñoz-Fernández, MA
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (04) : 365 - 368
  • [7] Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children
    Hainaut, M
    Ducarme, M
    Schandené, L
    Peltier, CA
    Marissens, D
    Zissis, G
    Mascart, F
    Levy, J
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (01) : 62 - 69
  • [8] Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children
    van Rossum, AMC
    de Groot, R
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (10) : 934 - 935
  • [9] Beneficial Effects of a Combination of Korean Red Ginseng and Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Patients
    Sung, Heungsup
    Jung, You-Sun
    Cho, Young-Keol
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (08) : 1127 - 1131
  • [10] Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy
    Ling, PD
    Vilchez, RA
    Keitel, WA
    Poston, DG
    Peng, RS
    White, ZS
    Visnegarwala, F
    Lewis, DE
    Butel, JS
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) : 1244 - 1249